肺心宁合剂配合西医疗法治疗慢性肺原性心脏病急性发作期60例临床观察

探讨肺心宁合剂对慢性肺原性心脏病(肺心病)急性发作期的治疗效果。治疗组60例患者和单纯西药治疗之对照组60例患者均以吸氧、解痉平喘、抗感染、纠正呼吸衰竭和心力衰竭为基础治疗。治疗组加用自制中药肺心宁合剂治疗。2组皆以15天为1个疗程,并于治疗前后检测血浆内皮素—1(ET—1)水平和血液流变学变化。结果治疗组显效率73.33％,总有效率93.34％;对照组显效率35％,总有效率68.34％,2组总有效率比较差异有显著性(P＜0.01)。血浆ET—1水平治疗组治疗后为(69.8±15.8)ng／L,显著低于对照组(78.1±13.5)ng／L(P＜0.01),治疗组治疗后血液流变学指标较治疗前及对照组治疗后明显下降(P＜0.05或P＜0.01)。提示肺心宁合剂对慢性肺心病急性发作期患者可明显提高总有效率,能降低血浆ET－1水平和改善血液流变学。疗效明显优于单纯西药治疗组。

Clinical Observation on 60 Cases of Chronic Pulmonary Heart Disease at Acute Attack Stage Treated with Fei Xin Ning Mixture Conbined with Western Medicine Therapy

Sixty cases of chronic pulmonary heart disease at acute attack stage in the treatment group and 60 cases of the control group were treated with oxygen - inspiration, relieving spasm and asthma, anti - infection, and correcting respiratory failure and heart failure as basic treatment. Self - made Chinese drug Fei Xin Ning Mixture was added to the treatment group. In the two groups. 15 days constituted one course. Plasma endothelin 1 (ET-1) level and hernorheologic indices were determined before and after treatment. Results indicated that the markedly effective rate, effectice rate and the total effective rate in the treatment group were 73. 33%. 20% and 93. 34% respectively, and 35%, 33. 34% and 68. 34% in the control group, with significant difference in the total effective rate between the two groups